



# **FP7 Health Work Programme 2013**

**Inmaculada Peñas Jiménez**  
**Infectious diseases and Public Health Unit**  
**Directorate Health**  
**DG Research & Innovation**  
**European Commission**



# **Collaborative research in the Health theme**

## **Main policy drivers:**

- **Improving health of European citizens**
- **Increasing competitiveness of European health-related industries and businesses**
- **Addressing global health issues, including emerging epidemics**

## **Budget:**

- **€6.1 billion over 7 years (2007-2013)**



# Collaborative research in the Health theme

## Emphasis on:

- **Translational research: translation of basic discoveries in clinical applications including scientific validation of experimental results**
- **Development and validation of new therapies, methods for health promotion and prevention:**
  - **Promotion of child health and healthy ageing**
  - **Diagnostic tools**
  - **Medical technologies**
  - **Efficient and sustainable healthcare systems**



## Key features for 2013 work programme

- *Key challenges:*
  - Brain research
  - Antimicrobial drug resistance
  - Comparative effectiveness research
- *36 topics*



## Key features for 2013 work programme

- *Two calls:*
  - **INNOVATION-1 (34 topics): €679 million**
  - **INNOVATION-2 (2 SME topics): €140 million**
- *Deadlines for submission:*
  - **INNOVATION-1: 2 October 2012**
  - **INNOVATION-2: 25 September 2012**



## General conditions 2013

- *Ethical issues: impact of the research and legislation*
- *Use of animals: protection and protocols*
- *Gender dimension of the research*
- *Socio-economic dimension of research: impact ( include patients and civil society organisations, policy makers, etc)*
- *Statistics*
- *Clear guidelines for clinical trials*



## **Horizontal topic relevant for the whole of theme health**

**50%  
SME**

### **HEALTH.2013.0-1 Boosting the translation of health research projects' results into innovative applications for health**

- To translate of high level scientific knowledge supported by FP6 and FP7 funding into applications and innovative products and services.



# Biotech, tools & technologies

## 1.3 - Suitability, safety, efficacy of therapies

**30%**  
Ind/SME

### *1.3-3 Safety and efficacy of therapeutic vaccines*

- To advance promising new therapeutic vaccines candidates into clinical safety and efficacy testing.





# Translating research for human health

## 2.2 – Research on the brain and related diseases, human development and ageing

**15%  
SME**

### ***2.2.1 Brain and brain-related diseases***

*2.2.1-3 Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment*

- To develop preventative and therapeutic strategies for paediatric conduct disorders characterised by aggressive and anti-social traits



# Translating research for human health

## 2.2 – Research on the brain and related diseases, human development and ageing

### ***2.2.1 Brain and brain-related diseases***

#### *2.2.1-5 Understanding and controlling pain*

- To identify more effective diagnostic and treatments



# Translating research for human health

## 2.3 – Translational research in major infectious diseases: to confront major threats to public health

### 2.3.0 *Cross-cutting priorities*

**30%  
SME**

#### 2.3.0-1 *Innovation in vaccines*

- To develop new, safe and effective vaccines whose research is advanced to initiate clinical testing in the early phases of the project for
  - ✓ ‘Universal’ influenza vaccines to protect from seasonal and pandemic influenza, or
  - ✓ Prophylactic vaccines for any of the neglected infectious diseases (list in the text of Work Programme).



# Translating research for human health

## **2.3 – Translational research in major infectious diseases: to confront major threats to public health**

### ***2.3.1 Anti-microbial drug resistance***

#### *2.3.1-2 Stratified approaches to antibacterial and/or antifungal treatment*

- To improve the administration of antibacterial and antifungal products to tailor them to the needs of individual patients



# Translating research for human health

## ***2.3.3 Potentially new and re-emerging epidemics***

### *2.3.3-1 Clinical management of patients in severe epidemics*

- To set up a multidisciplinary consortium with capacity for a rapid, harmonized and optimised approach to clinical management of patients in case of any severe infectious outbreak with pandemic potential or significant risk of major damage to health and socio-economics in the EU

**€24m**



# Translating research for human health

## ***2.3.4 Neglected infectious diseases***

**15%  
SME**

### *2.3.4-2 Drug development for neglected parasitic diseases*

- To bring together European and global attempts to discover and develop promising drug candidates to fight against neglected parasitic diseases (see work programme):
  - ✓ to establish a common drug discovery platform addressing at least 3 parasitic diseases, or:
  - ✓ to undertake advanced clinical testing of new or improved drug candidates, including new formulations of combinations of already approved drugs



# Translating research for human health

## 2.4 – Translational research in other major diseases

### 2.4.1 Cancer

*2.4.1-1 Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer*

- To improve survival of patients with metastatic cancer



# Translating research for human health

## 2.4 – Translational research in other major diseases

### 2.4.1 *Cancer*

#### 2.4.1-2 *Strengthening the cancer patient's immune system*

**30%**  
**Ind/SME**

- To improve the efficacy of cancer immunotherapeutic regimens





# Translating research for human health

## 2.4 – Translational research in other major diseases

### **2.4.1 Cancer**

*2.4.1-3 Investigator-driven supportive and palliative care clinical trials and observational studies*

- To improved comfort and quality of life of cancer patients or cancer survivors.



# Translating research for human health

## 2.4 – Translational research in other major diseases

### ***2.4.2 Cardiovascular diseases***

*2.4.2-1 Discovery research to reveal novel targets for cardiovascular disease treatment*

**30%  
SME**

- To provide new targets for future drug development in this area



# Translating research for human health

## 2.4 – Translational research in other major diseases

### ***2.4.2 Cardiovascular diseases***

*2.4.2-2 Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases*

- To inform patients, health care providers and decision makers about the technologies that are most effective for cardiovascular diseases



# Translating research for human health

## 2.4 – Translational research in other major diseases

### ***2.4.2 Cardiovascular diseases***

#### *2.4.2-3 Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan*

- To provide solid evidence based research to guide prevention and treatment of cardiovascular diseases at primary and secondary levels to yield to save in existing unsustainable health care systems



# Optimizing the delivery of healthcare

## 3.1 – Translating the results of clinical research outcome into clinical practice

*3.1-1 Comparative effectiveness research (CER) in health systems and health services interventions:*

- To assist policy and decision makers in the implementation of health system and health services interventions in view of improving patients outcomes, quality of life and the cost-effectiveness of interventions



# Optimizing the delivery of healthcare

**15%  
SME**

## 3.3 – Health promotion and prevention

### *3.3-1 Social innovation for health promotion*

- To identify more effective and efficient evidence-based strategies for reducing sedentary behaviour and increasing physical activity preventing related diseases.



## Other actions across the health theme

### 4.1 – Coordination and support actions across the theme

*4.1-5 Global initiative on gene-environment interactions in diabetes/obesity in specific populations*

- To create an international network of funders in the area of diabetes/obesity research enabling the translation of the results into policy, social and economic benefits.



## Other actions across the health theme

### 4.1 – Coordination and support actions across the theme

#### *4.1-6 Mapping chronic non-communicable diseases research activities*

- To contribute to develop evidence based policies in chronic non-communicable diseases.





## **On going project: FOCUS**

### **Fixed Dose Combination Drug for Secondary cardiovascular Prevention**

- €4,7 million of EU contribution.
- To analyse data from 40 clinical sites in Europe and 40 sites across Argentina, Brazil and Paraguay, establish a proof of concept of Fixed Dose Combination efficacy for secondary Cardio Vascular Diseases prevention and to understand of socio-economic factors that influence access and adherence to this treatment.
- It will help to improve the use of medication in patients with ischemic heart disease.



# Thank you

## **Contacts & Information:**

**FP7 Health web site:** <http://cordis.europa.eu/fp7/health>

**Participant Portal:** <http://ec.europa.eu/research/participants/portal>

To register as an **Expert:** <https://cordis.europa.eu/emmfp7/>

**FitForHealth:** [www.fitforhealth.eu](http://www.fitforhealth.eu)

**EC projects database:** [www.healthcompetence.eu](http://www.healthcompetence.eu)